Gonzaga Daniel T G, Souza Thiago M L, Andrade Viviane M M, Ferreira Vitor F, de C da Silva Fernando
Universidade Federal Fluminense, Departamento de Quimica Organica, Instituto de Quimica, Campus do Valonguinho, 24020-150, Niteroi-RJ, Brazil.
Fundacao Oswaldo Cruz, Presidencia da Fiocruz, Centro de Desenvolvimento Tecnologico em Saude, Instituto Oswaldo Cruz, Laboratorio de Imunofarmacologia, 21040-360 - Rio de Janeiro-RJ, Brazil.
Med Chem. 2018;14(3):242-248. doi: 10.2174/1573406413666170906121318.
Low molecular weight 1-Aryl-1H-1,2,3-triazoles are endowed with various types of biological activities, such as against cancer, HIV and bacteria. Despite the existence of six different classes of antiretroviral drugs in clinical use, HIV/AIDS continue to be an on growing public health problem.
In the present study, we synthesized and evaluated thirty 1-Aryl-1H-1,2,3-triazoles against HIV replication.
The compounds were prepared by Huisgen 1,3-dipolar cycloaddition protocol catalyzed by Cu(I) between aryl azides and propargylic alcohol followed by further esterification and etherification from a nucleophilic substitution with acid chlorides or alkyl bromides in good yields. The compounds were submitted to the inhibition of HIV replication and evaluation of their cytotoxicity. Initially, the compounds were screened at 10 µM and the most active were further evaluated in order to obtain some pharmacological parameters.
Thirty molecules were evaluated, six were selected - because they inhibited more than 80% HIV replication. We further showed that two of these compounds are 8-times more potent, and less cytotoxic, than nevirapine, an antiretroviral drug in clinical use.
We identified very simple triazoles with promissing antiretroviral activities that led to the development of new drugs against AIDS.
低分子量1-芳基-1H-1,2,3-三唑具有多种生物活性,如抗癌、抗HIV和抗菌活性。尽管临床上存在六种不同类别的抗逆转录病毒药物,但HIV/AIDS仍然是一个日益严重的公共卫生问题。
在本研究中,我们合成并评估了三十种1-芳基-1H-1,2,3-三唑对HIV复制的作用。
通过铜(I)催化的芳基叠氮化物与炔丙醇之间的Huisgen 1,3-偶极环加成反应制备化合物,随后通过与酰氯或烷基溴的亲核取代进行进一步的酯化和醚化反应,产率良好。对这些化合物进行HIV复制抑制和细胞毒性评估。最初,以10 μM的浓度对化合物进行筛选,并对活性最高的化合物进行进一步评估,以获得一些药理学参数。
评估了三十种分子,选择了六种——因为它们抑制HIV复制超过80%。我们进一步表明,其中两种化合物的效力比临床使用的抗逆转录病毒药物奈韦拉平高8倍,且细胞毒性更小。
我们鉴定出具有潜在抗逆转录病毒活性的非常简单的三唑类化合物,这为开发抗艾滋病新药带来了希望。